Literature DB >> 2255802

Nosocomial pneumonia in the 1990s: update of epidemiology and risk factors.

D E Craven1, T W Barber, K A Steger, M A Montecalvo.   

Abstract

Hospital-acquired pneumonia is the second most common nosocomial infection in the United States. Aspiration appears to be the major route for the entry of microorganisms into the lower respiratory tract. Nosocomial pneumonia may be caused by bacteria, viruses and fungi. Aerobic gram-negative bacilli and Staphylococcus aureus are the most common etiologic agents, but infection is usually polymicrobial. Risk factors for nosocomial pneumonia include host variables, colonization with nosocomial pathogens, and impaired response of pulmonary defenses to the microbial challenge. Bacteria causing nosocomial pneumonia may be part of the patient's endogenous flora, originate from the hands of hospital personnel, or result from the use of invasive devices. The mechanically ventilated patient has multiple risk factors that contribute to the high rate of nosocomial pneumonia. An understanding of the epidemiology and risk factors for nosocomial pneumonia is fundamental for implementation of preventive strategies to reduce patient morbidity, mortality, and hospital costs.

Entities:  

Mesh:

Year:  1990        PMID: 2255802

Source DB:  PubMed          Journal:  Semin Respir Infect        ISSN: 0882-0546


  22 in total

1.  Nosocomial lower respiratory tract infections: prevalence and risk factors in 14 Greek hospitals.

Authors:  D P Kofteridis; J A Papadakis; D Bouros; P Nikolaides; G Kioumis; S Levidiotou; E Maltezos; S Kastanakis; S Kartali; A Gikas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-12       Impact factor: 3.267

Review 2.  Nosocomial pneumonia: epidemiology and infection control.

Authors:  D E Craven; K A Steger; L M Barat; R A Duncan
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 3.  Systemic antibiotic treatment of nosocomial pneumonia.

Authors:  K E Unertl; F P Lenhart; H Forst; K Peter
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 4.  Nursing home-associated pneumonia, hospital-acquired pneumonia and ventilator-associated pneumonia: the contribution of dental biofilms and periodontal inflammation.

Authors:  Krishnan Raghavendran; Joseph M Mylotte; Frank A Scannapieco
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

Review 5.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features.

Authors:  E Bergogne-Bérézin; K J Towner
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

6.  Usefulness of Leeds Acinetobacter Medium for recovery of Acinetobacter species from respiratory specimens collected in an intensive care unit.

Authors:  J C Alados; J Serrano; J A García; C Miranda; G Orellana; M de la Rosa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-06       Impact factor: 3.267

7.  Characterization of the type 3 fimbrial adhesins of Klebsiella strains.

Authors:  T A Sebghati; T K Korhonen; D B Hornick; S Clegg
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

8.  Genetic relationships between respiratory pathogens isolated from dental plaque and bronchoalveolar lavage fluid from patients in the intensive care unit undergoing mechanical ventilation.

Authors:  Seok-Mo Heo; Elaine M Haase; Alan J Lesse; Steven R Gill; Frank A Scannapieco
Journal:  Clin Infect Dis       Date:  2008-12-15       Impact factor: 9.079

9.  Physicochemical characterization of hexetidine-impregnated endotracheal tube poly(vinyl chloride) and resistance to adherence of respiratory bacterial pathogens.

Authors:  David S Jones; James G McGovern; A David Woolfson; Colin G Adair; Sean P Gorman
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

10.  Human neutrophil chemotaxis is modulated by capsule and O antigen from an extraintestinal pathogenic Escherichia coli strain.

Authors:  Thomas A Russo; Bruce A Davidson; Diana M Topolnycky; Ruth Olson; Stacy A Morrill; Paul R Knight; Philip M Murphy
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.